Trial of Rucaparlb in ProsTate IndicatiONs 3 (TRITON3): An International, Multicenter, Randomized, Open-Label Phase 3 Study of Rucaparib vs Physician's Choice of Therapy for Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC) Associated with Homologous Recombination Deficiency (HRD)

Charles J. Ryan, ¹ Simon Watkins, ² Darrin Despain, ² Chris Karlovich, ^{2,*} Andy Simmons,² Tony Golsorkhi,² Simon Chowdhury³

¹UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA; ²Clovis Oncology, Inc., Boulder, CO; ³Guy's Hospital & Sarah Cannon Research Institute, London, UK

*Former affiliation: Clovis Oncology; current affiliation: Frederick National Laboratory for Cancer Research and the National Cancer Institute, Bethesda, MD.

Abstract: TPS5087

INTRODUCTION

- Germline and somatic mutations in BRCA1, BRCA2, ATM, and other homologous recombination (HR) DNA-repair genes have been identified in advanced prostate cancer (including mCRPC) at frequencies of 20%–25% or higher^{1,2}
- Poly(ADP-ribose) polymerase (PARP) inhibitors are a promising class of agents that are synthetically lethal to cells with HRD³⁻⁵
- In preclinical studies, the PARP inhibitor rucaparib demonstrated potent cytotoxicity in prostate cancer cell lines with CRISPR-mediated knockout of BRCA2 or ATM⁶
- In a phase 2 study of the PARP inhibitor olaparib (NCT01682772) in patients with mCRPC, 14 of 16 evaluable patients who had progressed on ≥1 prior chemotherapy and responded to olaparib treatment had a tumor alteration in an HR gene, including BRCA1, BRCA2, and ATM²
- These data provide a rationale for further investigation of the PARP inhibitor rucaparib in patients with mCRPC and an alteration in an HR gene

TRITON3 TRIAL OVERVIEW

 TRITON3 (CO-338-063; NCT02975934) is an international, multicenter, open-label, phase 3 study evaluating rucaparib 600 mg twice daily vs physician's choice of abiraterone, enzalutamide, or docetaxel as treatment for patients with mCRPC who have a deleterious germline or somatic mutation in BRCA1, BRCA2, or ATM (Figure 1)

PATIENT ELIGIBILITY

Table 1. Key Patient Inclusion/Exclusion Criteria

Key inclusion criteria

- ≥18 years of age
- Histologically or cytologically confirmed adenocarcinoma or poorly differentiated carcinoma of the prostate
- Surgically or medically castrated, with serum testosterone levels of ≤50 ng/dL (1.73 nM)
- Evidence of disease progression after treatment with 1 prior next-generation, AR-signaling directed therapy (abiraterone acetate, enzalutamide, or investigational agent) for castration-resistant disease (treatment with the older antiandrogen therapies, such as bicalutamide, flutamide, and nilutamide, are not counted toward this limit)
- BRCA1, BRCA2, or ATM gene mutation identified by local or central laboratory testinga
- Eastern Cooperative Oncology Group Performance Status 0 or 1

Key exclusion criteria

- Prior chemotherapy (eg, docetaxel, mitoxantrone, cyclophosphamide, or platinumbased agents) for mCRPC
- Prior PARP inhibitor treatment

Primary endpoint

ORR and DOR by

Overall survival

and ≥90%

PRO[‡]

Clinical benefit rate

modified RECIST in

review

Radiographic PFS[†] by

independent radiology

Key secondary endpoints

patients with measurable

nodal/visceral disease

PSA response of ≥50%

Time to PSA progression

Safety and tolerability

- Initiated bisphosphonate or denosumab therapy or adjusted bisphosphonate or denosumab dose/regimen within 4 weeks prior to first dose of rucaparib
- Symptomatic and/or untreated CNS metastases
- Active secondary malignancy, with the exception of curatively treated nonmelanoma skin cancer, carcinoma in situ, or superficial bladder cancer
- Received treatment with chemotherapy, hormonal therapy (with the exception of LHRH analog), radiation, antibody therapy, immunotherapy, gene therapy, angiogenesis inhibitors, or experimental drugs ≤14 days prior to first dose of study drug

^aPatients with a known deleterious BRCA1, BRCA2, or ATM mutation (documented in the patient's medical record) should also submit archival tumor tissue, if available; biopsy of visceral/nodal metastasis preferred.

AR, androgen receptor; CNS, central nervous system; LHRH, luteinizing hormone-releasing hormone; mCRPC, metastatic castration-resistant prostate cancer; PARP, poly(ADP-ribose) polymerase.

PLASMA-BASED COMPANION DIAGNOSTIC

- There are significant challenges in collecting and analyzing biopsy specimens from patients with mCRPC
- TRITON3 will explore the use of circulating tumor DNA (ctDNA) purified from blood as a noninvasive companion diagnostic
- Pretreatment blood samples will be collected from all patients and analyzed for BRCA1, BRCA2, and ATM mutations in ctDNA
- A central retrospective analysis will be performed to determine the concordance between HR gene alterations identified in tumor tissue samples and ctDNA obtained from plasma

TRIAL SUMMARY

- Deleterious mutations in BRCA1, BRCA2, and ATM have been identified in patients with mCRPC, 1,2 and these patients could potentially benefit from treatment with a PARP inhibitor such as rucaparib
- The TRITON3 phase 3 study aims to assess the efficacy of rucaparib vs physician's choice of treatment for patients with mCRPC associated with HRD who progressed on prior androgen receptor-signalling directed therapy and have not received chemotherapy in the castration-resistant setting
- TRITON3 is actively recruiting patients, with a goal of enrolling 400 patients from >100 sites worldwide (Figure 2)
- Rucaparib is also being evaluated in the TRITON2 phase 2 study (NCT02952534), which will assess response to rucaparib in patients with mCRPC who have a deleterious germline or somatic BRCA1, BRCA2, or ATM mutation, and in an exploratory cohort of patients with an alteration in any of 12 additional prespecified HR genes (eg, RAD51C, RAD51D, or PALB2)

Figure 1. TRITON3 Trial Schema

Screening

Key eligibility criteria

- Metastatic, castrationresistant prostate cancer
- Deleterious somatic or germline mutation in BRCA1, BRCA2, or ATM as determined by local testing,* analysis of screening tissue biopsy or archival tumor tissue, or central testing of ctDNA from blood
- No prior PARP inhibitor therapy
- No prior chemotherapy for mCRPC

Pretreatment blood samples will be collected from all patients for analysis of BRCA1, BRCA2, and ATM gene mutations in ctDNA

Treatment

Rucaparib 600 mg BID Radiographic progression or (n=267)treatment discontinuation for other reason

Randomization 2:1

Physician's choice of

(n=133): **Docetaxel (plus prednisone)**

75 mg/m² every 21 days (max 10 cycles)

Abiraterone acetate (plus prednisone) 1000 mg QD

Enzalutamide 160 mg QD

Post-treatment

- 28-day follow-up visit
- Long-term follow-up
- Disease and PRO assessments every 8–12 weeks for patients who discontinue for reason other than progression

 All patients to be followed every 12 weeks for survival, subsequent therapies, and development of secondary malignancies

 Patients receiving clinical benefit with rucaparib may be considered for continued treatment beyond progression

> Patients who progress on comparator treatment may be considered for

Optional crossover

crossover to rucaparib

*Patients with a known BRCA1, BRCA2, or ATM mutation (documented in the patient's medical record) should also submit archival tumor tissue, if available; biopsy of visceral/nodal metastasis preferred.

†Modified Response Evaluation Criteria In Solid Tumors version 1.1 (RECIST)⁷ criteria will be used to document radiographic response in soft-tissue (visceral and nodal) disease, and Prostate Cancer Clinical Trials Working Group Guidelines Version 38 criteria will be used to document radiographic progression of bone lesions.

[‡]Patient-reported outcomes (PROs) using the EQ-5D questionnaire, Functional Assessment of Cancer Therapy–Prostate, and Brief Pain Inventory–Short Form instruments. BID, twice daily; ctDNA, circulating tumor DNA; DOR, duration of response; mCRPC, metastatic castration-resistant prostate cancer; ORR, objective response rate; PARP, poly(ADP-ribose) polymerase; PFS, progression-free survival; PRO, patient-reported outcome; PSA, prostate-specific antigen; QD, once daily.

Figure 2. Countries Participating in TRITON3 Australia Belgium Canada Denmark France Germany Israel Republic of Ireland United Kingdom **United States** TRITO 3

REFERENCES

- Robinson et al. Cell. 2015;161:1215-28.
- Mateo et al. N Engl J Med. 2015;373:1697-708.
- O'Connor. Mol Cell. 2015;60:547-60.
- Lee et al. Ann Oncol. 2014;25:32-40.
- Scott et al. J Clin Oncol. 2015;33:1397-406.
- 6. Nguyen et al. Presented at AACR 2017. Available at
- http://www.abstractsonline.com/pp8/#!/4292/presentation/1187. Accessed April 27, 2017. Eisenhauer et al. Eur J Cancer. 2009;45:228-47.
- Scher et al. J Clin Oncol. 2016;34:1402-18.
- 9. EuroQol Group. Health Policy. 1990;16:199-208.
- 10. Esper et al. *Urology*. 1997;50:920-8.
- 11. Cleeland et al. Ann Acad Med Singapore. 1994;23:129-38. **ACKNOWLEDGMENTS**

The study is funded by Clovis Oncology, Inc. Medical writing and editorial support was funded by Clovis Oncology and provided by Nathan Yardley and Shannon Davis of Ashfield Healthcare Communications.

Copies of this poster obtained through Quick Response (QR) Code are for personal use only and may not be reproduced without permission from ASCO® and the author of this poster (contact: Charles.Ryan@ucsf.edu).

